These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15993591)

  • 1. SAR and biological evaluation of novel trans-3,4-dimethyl-4-arylpiperidine derivatives as opioid antagonists.
    Díaz N; Benvenga M; Emmerson P; Favors R; Mangold M; McKinzie J; Patel N; Peters S; Quimby S; Shannon H; Siegel M; Statnick M; Thomas E; Woodland J; Surface P; Mitch C
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3844-8. PubMed ID: 15993591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereochemical influences upon the opioid ligand activities of 4-alkyl-4-arylpiperidine derivatives.
    Casy AF; Dewar GH; al Deeb OA
    Chirality; 1989; 1(3):202-8. PubMed ID: 2561991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo rat brain opioid receptor binding of LY255582 assessed with a novel method using LC/MS/MS and the administration of three tracers simultaneously.
    Need AB; McKinzie JH; Mitch CH; Statnick MA; Phebus LA
    Life Sci; 2007 Oct; 81(17-18):1389-96. PubMed ID: 17935738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central administration of the opioid antagonist, LY255582, decreases short- and long-term food intake in rats.
    Levine AS; Grace M; Billington CJ; Zimmerman DM
    Brain Res; 1991 Dec; 566(1-2):193-7. PubMed ID: 1667609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Michaut M; Ye HF; Graczyk TM; Belanger S; Herbertz T; Yap GP; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7278-89. PubMed ID: 17149858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a new scaffold for opioid receptor antagonism based on the 2-amino-1,1-dimethyl-7-hydroxytetralin pharmacophore.
    Grundt P; Williams IA; Lewis JW; Husbands SM
    J Med Chem; 2004 Oct; 47(21):5069-75. PubMed ID: 15456250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure activity studies of a series of 4-(m-OH phenyl) piperidines.
    Loew G; Lawson J; Toll L; Uyeno E; Frenking G; Polgar W
    NIDA Res Monogr; 1986; 75():49-52. PubMed ID: 3123966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists.
    Xia M; Hou C; Pollack S; Brackley J; DeMong D; Pan M; Singer M; Matheis M; Olini G; Cavender D; Wachter M
    Bioorg Med Chem Lett; 2007 Nov; 17(21):5964-8. PubMed ID: 17869105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and structure-activity relationships of a new series of 2alpha-substituted trans-4,5-dimethyl-4-(3-hydroxyphenyl)piperidine as mu-selective opioid antagonists.
    Le Bourdonnec B; Goodman AJ; Michaut M; Ye HF; Graczyk TM; Belanger S; DeHaven RN; Dolle RE
    Bioorg Med Chem Lett; 2006 Feb; 16(4):864-8. PubMed ID: 16298525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and evaluation of naphthol- and carbazole-containing fluorescent sigma ligands as potential probes for receptor binding studies.
    Ferorelli S; Abate C; Colabufo NA; Niso M; Inglese C; Berardi F; Perrone R
    J Med Chem; 2007 Sep; 50(19):4648-55. PubMed ID: 17713896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural requirements for affinity and intrinsic activity at the opiate receptor defined in 4-phenylpiperidine and related series.
    Zimmeman DM; Smits SE; Hynes MD; Cantrell BE; Reamer M; Nickander R
    NIDA Res Monogr; 1982 Apr; 41():112-8. PubMed ID: 6289111
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of opioid receptor ligands injected into the rostral lateral hypothalamus on c-fos and feeding behavior.
    Li D; Olszewski PK; Shi Q; Grace MK; Billington CJ; Kotz CM; Levine AS
    Brain Res; 2006 Jun; 1096(1):120-4. PubMed ID: 16716266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains.
    Shen DM; Shu M; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
    Bioorg Med Chem Lett; 2004 Feb; 14(4):935-9. PubMed ID: 15012997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
    Cai TB; Zou Z; Thomas JB; Brieaddy L; Navarro HA; Carroll FI
    J Med Chem; 2008 Mar; 51(6):1849-60. PubMed ID: 18307295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel sigma receptor ligands: synthesis and biological profile.
    Prezzavento O; Campisi A; Ronsisvalle S; Li Volti G; Marrazzo A; Bramanti V; Cannavò G; Vanella L; Cagnotto A; Mennini T; Ientile R; Ronsisvalle G
    J Med Chem; 2007 Mar; 50(5):951-61. PubMed ID: 17328523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and structure-activity relationships of novel histamine H1 antagonists: indolylpiperidinyl benzoic acid derivatives.
    Fonquerna S; Miralpeix M; Pagès L; Puig C; Cardús A; Antón F; Cárdenas A; Vilella D; Aparici M; Calaf E; Prieto J; Gras J; Huerta JM; Warrellow G; Beleta J; Ryder H
    J Med Chem; 2004 Dec; 47(25):6326-37. PubMed ID: 15566302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonists.
    Zischinsky G; Osterkamp F; Vossmeyer D; Zahn G; Scharn D; Zwintscher A; Stragies R
    Bioorg Med Chem Lett; 2010 Jan; 20(1):65-8. PubMed ID: 19959360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
    Le Bourdonnec B; Goodman AJ; Graczyk TM; Belanger S; Seida PR; DeHaven RN; Dolle RE
    J Med Chem; 2006 Dec; 49(25):7290-306. PubMed ID: 17149859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptides that regulate food intake: antagonism of opioid receptors reduces body fat in obese rats by decreasing food intake and stimulating lipid utilization.
    Statnick MA; Tinsley FC; Eastwood BJ; Suter TM; Mitch CH; Heiman ML
    Am J Physiol Regul Integr Comp Physiol; 2003 Jun; 284(6):R1399-408. PubMed ID: 12736177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.